Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Progressive Clear all
Completed Not applicable Interventional

Support for People Undergoing Chemotherapy

NCT00740038
View directory record Official record
Conditions
Quality of Life, Cancer
Interventions
Stress Management training, Exercise Training, Usual care, Combined stress management and exercise training
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strength Training Induced Alterations in Markers of Immune Function

NCT01450852
View directory record Official record
Conditions
Inflammation
Interventions
Strength Training
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 30 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 24, 2026, 2:14 PM EDT
Recruiting Not applicable Interventional

Feasibility of an In-home Standing and Walking Intervention for Infants With and at High Risk of Cerebral Palsy

NCT05781438
View directory record Official record
Conditions
Cerebral Palsy
Interventions
In-home standing and walking intervention
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
5 Months to 2 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 24, 2026, 2:14 PM EDT
Recruiting No phase listed Observational

PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

NCT06855329
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Aurora, Colorado • Worcester, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

NCT04960202
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332, Ritonavir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
73
States / cities
Pelham, Alabama • Mesa, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional

Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21

NCT05452902
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
EXCAP Exercise, Nutrition Education
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

NCT00076102
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibroma, Plexiform
Interventions
Pirfenidone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

NCT01564537
View directory record Official record
Conditions
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
18
States / cities
Little Rock, Arkansas • Anaheim, California • Berkeley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise

NCT00387712
View directory record Official record
Conditions
Stroke, Inflammation
Interventions
Velocity based treadmill training, Duration based treadmill training
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
aldesleukin, allogeneic large multivalent immunogen vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

NCT00003819
View directory record Official record
Conditions
Prostate Cancer
Interventions
QS21, TF(c)-KLH conjugate vaccine, Thomsen-Friedenreich antigen, keyhole limpet hemocyanin
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional

Evaluating the Effectiveness of a Community Exercise Program to Reduce the Risk of Metabolic Syndrome Among Black Americans

NCT00783445
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Community-Based Exercise Program (C-FIT), Self-Help Exercise Program (HOME)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 24, 2026, 2:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Not yet recruiting Not applicable Interventional

Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients

NCT07840599
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Breast Cancer (MBC), Metastatic Breastcancer
Interventions
Core Intervention, EHR Integration (On v. Off), Weekly Coaching, Social+ (on v. off), Static Goal Setting, Bi-Weekly Coaching, Highly Tailored Goal Setting
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Not applicable Interventional

Nordic Hamstring Exercise After ACL Reconstruction Reconstruction

NCT05738200
View directory record Official record
Conditions
ACL Injury, Muscle Weakness, Neuromuscular Manifestations
Interventions
Nordic Hamstring Exercise
Other
Lead sponsor
University of Toledo
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT03391765
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 24, 2026, 2:14 PM EDT
Active, not recruiting Not applicable Interventional

The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

NCT03881098
View directory record Official record
Conditions
Lung Cancer
Interventions
Bronchoscopies, Sputum Sample, Venipuncture
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 1 Interventional Results available

An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment

NCT05051644
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
Steps 2 Change (S2C), Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 24, 2026, 2:14 PM EDT
Recruiting Early Phase 1 Interventional

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
View directory record Official record
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 24, 2026, 2:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

NCT03572634
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, CLL, SLL, Small Lymphocytic Lymphoma
Interventions
TP-0903, TP-0903 and ibrutinib combination therapy
Drug · Combination Product
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 24, 2026, 2:14 PM EDT
Withdrawn Phase 2 Interventional

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

NCT04629209
View directory record Official record
Conditions
Glioblastoma
Interventions
ONC201
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 24, 2026, 2:14 PM EDT
Completed Phase 3 Interventional

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

NCT00379470
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
NovoTTF-100A
Device
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 24, 2026, 2:14 PM EDT